Feb 18, 2025, 14:44
Tanja Obradovic: Another step in the global move toward value-based therapeutic options
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn by Dan Ollendorf, Chief Scientific Officer and Director of HTA Methods and Engagement at the Institute for Clinical and Economic Review, adding:
“New initiative by ICER NICE and Canada’s HTA on evaluation of the pharmacoeconomic impact of new therapies highlighted by Dan Ollendorf. Another step in the global move toward value-based therapeutic options.”
Quoting Dan Ollendorf’s post:
“It’s critical not to underestimate the importance of this initiative – allowing independent and scientific conversation when such conversations are currently under attack.”
More posts featuring Tanja Obradovic.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 18, 2025, 14:15
Feb 18, 2025, 13:58
Feb 18, 2025, 12:47
Feb 18, 2025, 11:41